CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo

CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo

Wei Meng,1,* Jiajia Wang,1,* Baocheng Wang,1,* Fang Liu,2 Meng Li,2 Yang Zhao,1 Chenran Zhang,1 Qifeng Li,1 Juxiang Chen,3 Liye Zhang,4 Yujie Tang,1,2 Jie Ma1 1Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Repub...

Full description

Bibliographic Details
Main Authors: Meng W, Wang J, Wang B, Liu F, Li M, Zhao Y, Zhang C, Li Q, Chen J, Zhang L, Tang Y, Ma J
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:Cancer Management and Research
Subjects:
THZ1
CDK7
GBM
epigenetic targeted therapy
transcriptional addiction
Online Access:https://www.dovepress.com/cdk7-inhibition-is-a-novel-therapeutic-strategy-against-gbm-both-in-vi-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/cdk7-inhibition-is-a-novel-therapeutic-strategy-against-gbm-both-in-vi-peer-reviewed-article-CMAR

Similar Items